CXCR3, a double-edged sword in tumor progression and angiogenesis

Biochim Biophys Acta. 2013 Dec;1836(2):287-95. doi: 10.1016/j.bbcan.2013.08.002. Epub 2013 Aug 27.

Abstract

CXC chemokines are involved in chemotaxis, regulation of cell growth, induction of apoptosis and modulation of angiostatic effects. CXCL9, CXCL10, CXCL11, CXCL4 and its variant CXCL4L1 are members of the CXC chemokine family, which bind to the CXCR3 receptor to exert their biological effects. These chemokines are associated with a variety of human diseases including chronic inflammation, immune dysfunction, cancer and metastasis. In this review, we focus on accumulating evidence demonstrating the pivotal role of CXCR3 in tumor progression. Its effects are mediated directly in tumor cells or indirectly through the regulation of angiogenesis and tumor immunity. Understanding the emerging role of CXCR3 and its signaling mechanisms further validates this receptor as a biomarker and therapeutic target for tumor progression and tumor angiogenesis.

Keywords: Angiogenesis; CXC chemokines; CXCR3; Cancer; Tumor immunity; Tumor invasion.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cell Transformation, Neoplastic / pathology*
  • Chemokines, CXC / metabolism*
  • Disease Progression
  • Humans
  • Neoplasms / blood supply
  • Neoplasms / metabolism
  • Neoplasms / pathology*
  • Neovascularization, Pathologic*
  • Receptors, CXCR3 / metabolism*

Substances

  • Chemokines, CXC
  • Receptors, CXCR3